Nextblue Fund II has invested in Montreal-based Eli Health, which is transforming hormone monitoring through its innovative saliva-based testing kit, Hormometer™.

Target Company Overview

Nextblue Fund II has invested in Eli Health, a Montreal-based startup pioneering hormone monitoring through innovative saliva-based home testing kits called Hormometer™. This healthcare innovation seeks to empower women's health by providing an accessible and convenient method for assessing hormonal fluctuations.

The Hormometer™ simplifies the hormone testing process by allowing users to collect saliva samples easily and analyze results with a smartphone camera. The product stands out due to its capability to track hormonal patterns and trends over time, offering valuable insights into individual hormonal health. Eli Health has initially rolled out beta versions of testing kits for cortisol and progesterone, with plans to expand to more hormones in the future.

Industry Overview in Canada

In Canada, the healthcare sector is increasingly focusing on personalized medical services and the management of individual health data. This trend mirror